Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CRDL.TO
- Price
- 1.31
- Stock movement up
- +0.07 (5.65%)
- Company name
- Cardiol Therapeutics Inc Class A
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 106.90M
- Ent value
- 93.83M
- Price/Sales
- -
- Price/Book
- 6.96
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -51.30%
- 3 year return
- -15.74%
- 5 year return
- -12.19%
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
CRDL.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 6.96 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 81.60M |
| EPS (TTM) | -0.43 |
| FCF per share (TTM) | -0.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -255.19K |
| Operating income (TTM) | -32.89M |
| Net income (TTM) | -29.34M |
| EPS (TTM) | -0.43 |
| EPS (1y forward) | -0.38 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 24.02M |
| Net receivables | 242.42K |
| Total current assets | 25.88M |
| Goodwill | 0.00 |
| Intangible assets | 168.14K |
| Property, plant and equipment | 1.00M |
| Total assets | 26.31M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 164.27K |
| Total current liabilities | 10.81M |
| Total liabilities | 10.95M |
| Shareholder's equity | 15.36M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -21.58M |
| Capital expenditures (TTM) | 23.54K |
| Free cash flow (TTM) | -15.13M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -190.99% |
| Return on Assets | -111.50% |
| Return on Invested Capital | -190.72% |
| Cash Return on Invested Capital | -98.33% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.26 |
| Daily high | 1.31 |
| Daily low | 1.23 |
| Daily Volume | 55K |
| All-time high | 8.13 |
| 1y analyst estimate | 11.00 |
| Beta | 0.70 |
| EPS (TTM) | -0.43 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| CRDL.TO | S&P500 | |
| Current price drop from All-time high | -83.89% | -12.89% |
| Highest price drop | -92.25% | -56.47% |
| Date of highest drop | 6 Apr 2023 | 9 Mar 2009 |
| Avg drop from high | -65.90% | -11.07% |
| Avg time to new high | 106 days | 12 days |
| Max time to new high | 1541 days | 1805 days |
COMPANY DETAILS
Marketcap
106.90M
Marketcap category
Small-cap
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
April 2, 2025
Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the P...
April 1, 2025
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing ant...
March 3, 2025
Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure Toronto, Ontario--(Newsfi...
February 20, 2025
Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the researc...
February 4, 2025
Cardiol Therapeutics President and CEO, David ElsleyNEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President a...
December 19, 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support adva...
November 18, 2024
Company advancing late-stage clinical programs with novel therapies that target underserved heart diseasesNEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market ins...
November 13, 2024
MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned P...
October 22, 2024
Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the resear...
October 11, 2024
Next page